White House announces most-favored-nation deals with nine more manufacturers

The Trump administration announced on August 31, 2026, that it had reached most-favored-nation (MFN) pricing agreements with nine additional pharmaceutical manufacturers, according to a White House fact sheet referenced among related releases tied to the TrumpRx.gov program ^[1]. The announcement builds on a pricing push that began with an executive order signed May 12, 2025, and a wave of manufacturer letters sent July 31, 2025 ^[1].

TrumpRx.gov itself launched February 5, 2026, with discounts from the first five companies to sign MFN deals: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer ^[1]. At launch, the site listed price cuts on 40 branded drugs, including some of the country's most-used GLP-1 medicines and fertility treatments ^[1]. Ozempic's monthly price was set to fall from $1,028 to an average of $350, with some doses as low as $199, while injectable Wegovy was to drop from $1,349 to an average of $350, also as low as $199 depending on strength ^[1]. The Wegovy pill was listed at a new low of $149 depending on dosage, and Zepbound was set to fall from $1,088 to an average of $346, with some doses as low as $299 ^[1].

The February fact sheet also detailed savings on fertility drugs, including Gonal-F as low as $168 per pen, Cetrotide falling from $316 to $22.50, and Ovidrel dropping from $251 to $84, with the administration estimating families could save more than $2,000 per treatment cycle on average ^[1]. Other listed discounts covered inhalers, a topical ointment, insulin, and a menopause drug, showing the program was never limited to GLP-1s alone ^[1].

According to the source material reviewed, the administration says it has now announced 16 manufacturer deals since September 30, 2025, aimed at bringing U.S. prices in line with those paid in other developed nations ^[1]. The August 31 fact sheet is described in the same set of releases as covering nine additional manufacturers, consistent with the summary that this round further broadens the list of drugs carried on TrumpRx.gov beyond the original GLP-1 and fertility categories ^[1]. However, the specific manufacturers, drug names, and new prices tied to this particular round of nine deals are not detailed in the source material available for this article, so those specifics are not yet known from what has been reviewed.

Why it matters for patients

For people taking semaglutide products such as Ozempic, Wegovy, or Rybelsus, or tirzepatide products such as Mounjaro or Zepbound, the practical question is whether new manufacturers joining the MFN framework will bring additional discounts on GLP-1 drugs specifically, or mainly add unrelated categories of medicine to TrumpRx.gov. The February 2026 fact sheet shows that pricing under this program depends on the manufacturer, the drug, and the dosage strength, with savings accessed either through printable coupons or manufacturer-run channels integrated into the website ^[1]. That structure means a patient's actual out-of-pocket price can vary depending on which company makes their prescribed drug and which discount mechanism applies.

Because the source material for this article does not include the detailed contents of the August 31 announcement, patients cannot yet confirm from it whether their specific GLP-1 medication is affected by this newest round of deals, or whether the nine new manufacturers make GLP-1 drugs at all.

What happens next

The White House has said additional drugs from companies signing MFN deals will keep being added to TrumpRx.gov over time ^[1]. Separately, the administration has called on Congress to pass what it calls The Great Healthcare Plan, which would seek to codify MFN-related savings into law, a step announced January 15, 2026 ^[1]. Whether and when that legislation advances, and which drugs from the nine newly announced manufacturers appear on TrumpRx.gov, are not detailed in the material reviewed for this story.